These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31271662)

  • 1. Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells.
    Xu X; Wang L; Hu L; Dirks WG; Zhao Y; Wei Z; Chen D; Li Z; Wang Z; Han Y; Wei L; Drexler HG; Hu Z
    Int J Cancer; 2020 Jan; 146(2):400-412. PubMed ID: 31271662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JMJD1C-regulated lipid synthesis contributes to the maintenance of
    Qi D; Wang J; Zhao Y; Yang Y; Wang Y; Wang H; Wang L; Wang Z; Xu X; Hu Z
    Leuk Lymphoma; 2022 Sep; 63(9):2149-2160. PubMed ID: 35468015
    [No Abstract]   [Full Text] [Related]  

  • 3. Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia.
    Izaguirre-Carbonell J; Christiansen L; Burns R; Schmitz J; Li C; Mokry RL; Bluemn T; Zheng Y; Shen J; Carlson KS; Rao S; Wang D; Zhu N
    Blood Adv; 2019 May; 3(9):1499-1511. PubMed ID: 31076406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulators of histone demethylase JMJD1C selectively target leukemic stem cells.
    Yang Y; Zhang X; Zhang X; Wang Y; Wang X; Hu L; Zhao Y; Wang H; Wang Z; Wang H; Wang L; Dirks WG; Drexler HG; Xu X; Hu Z
    FEBS Open Bio; 2021 Jan; 11(1):265-277. PubMed ID: 33289299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. shRNA screening identifies JMJD1C as being required for leukemia maintenance.
    Sroczynska P; Cruickshank VA; Bukowski JP; Miyagi S; Bagger FO; Walfridsson J; Schuster MB; Porse B; Helin K
    Blood; 2014 Mar; 123(12):1870-82. PubMed ID: 24501218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone demethylase JMJD1C promotes the polarization of M1 macrophages to prevent glioma by upregulating miR-302a.
    Zhong C; Tao B; Yang F; Xia K; Yang X; Chen L; Peng T; Xia X; Li X; Peng L
    Clin Transl Med; 2021 Sep; 11(9):e424. PubMed ID: 34586733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.
    Lynch JR; Salik B; Connerty P; Vick B; Leung H; Pijning A; Jeremias I; Spiekermann K; Trahair T; Liu T; Haber M; Norris MD; Woo AJ; Hogg P; Wang J; Wang JY
    Leukemia; 2019 Jun; 33(6):1400-1410. PubMed ID: 30622285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.
    Chen M; Zhu N; Liu X; Laurent B; Tang Z; Eng R; Shi Y; Armstrong SA; Roeder RG
    Genes Dev; 2015 Oct; 29(20):2123-39. PubMed ID: 26494788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Potentials of Inhibition of Jumonji C Domain-containing Demethylases in Acute Myeloid Leukemia.
    Koca D; Hastar N; Engür S; Kiraz Y; Ulu GT; Çekdemir D; Baran Y
    Turk J Haematol; 2020 Feb; 37(1):5-12. PubMed ID: 31833715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
    Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.
    Xu X; Nagel S; Quentmeier H; Wang Z; Pommerenke C; Dirks WG; Macleod RAF; Drexler HG; Hu Z
    Leuk Lymphoma; 2018 Jan; 59(1):204-213. PubMed ID: 28540746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia.
    Kim JY; Kim KB; Eom GH; Choe N; Kee HJ; Son HJ; Oh ST; Kim DW; Pak JH; Baek HJ; Kook H; Hahn Y; Kook H; Chakravarti D; Seo SB
    Mol Cell Biol; 2012 Jul; 32(14):2917-33. PubMed ID: 22615488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein complex interactor analysis and differential activity of KDM3 subfamily members towards H3K9 methylation.
    Brauchle M; Yao Z; Arora R; Thigale S; Clay I; Inverardi B; Fletcher J; Taslimi P; Acker MG; Gerrits B; Voshol J; Bauer A; Schübeler D; Bouwmeester T; Ruffner H
    PLoS One; 2013; 8(4):e60549. PubMed ID: 23593242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
    Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
    Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative integromics on JMJD1C gene encoding histone demethylase: conserved POU5F1 binding site elucidating mechanism of JMJD1C expression in undifferentiated ES cells and diffuse-type gastric cancer.
    Katoh M; Katoh M
    Int J Oncol; 2007 Jul; 31(1):219-23. PubMed ID: 17549425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of histone demethylase JMJD1C attenuates cardiac hypertrophy and fibrosis induced by angiotensin II.
    Zhang S; Lu Y; Jiang C
    J Recept Signal Transduct Res; 2020 Aug; 40(4):339-347. PubMed ID: 32122211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.
    Wang L; Chang J; Varghese D; Dellinger M; Kumar S; Best AM; Ruiz J; Bruick R; Peña-Llopis S; Xu J; Babinski DJ; Frantz DE; Brekken RA; Quinn AM; Simeonov A; Easmon J; Martinez ED
    Nat Commun; 2013; 4():2035. PubMed ID: 23792809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase.
    Yoshihama Y; LaBella KA; Kim E; Bertolet L; Colic M; Li J; Shang X; Wu CJ; Spring DJ; Wang YA; Hart T; DePinho RA
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34475205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in JMJD1C are involved in Rett syndrome and intellectual disability.
    Sáez MA; Fernández-Rodríguez J; Moutinho C; Sanchez-Mut JV; Gomez A; Vidal E; Petazzi P; Szczesna K; Lopez-Serra P; Lucariello M; Lorden P; Delgado-Morales R; de la Caridad OJ; Huertas D; Gelpí JL; Orozco M; López-Doriga A; Milà M; Perez-Jurado LA; Pineda M; Armstrong J; Lázaro C; Esteller M
    Genet Med; 2016 Apr; 18(4):378-85. PubMed ID: 26181491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.